Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic
Evaluation of Children Who Were Underwent Endoscopic Procedures in the Normalization Process of Covid-19 Pandemic
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Endoscopic methods are frequently used in the diagnosis of gastrointestinal system pathologies in children. In the investigators' center, which is a pandemic hospital, only emergency endoscopic procedures were performed during the pandemic period, while emergency and elective endoscopic procedures are performed in accordance with the recommendations of the Ministry of Health during the normalization process. Staff and patients in endoscopy units are at risk for COVID-19 infection by inhalation of airborne droplets, conjunctival contact, and potential fecal-oral contamination. In order to reduce the risk of contamination, according to the recommendations of the European Gastrointestinal Endoscopy Association (ESGE); proper cleaning of endoscopic devices, non-reuse of disposable devices, cleaning the endoscopy hall with a disinfectant solution, use of gowns FFP2 / 3 masks and jewelry during the procedure, handwashing with soap and hand disinfection is recommended before and after each procedure. In addition, it is recommended that patients who have undergone endoscopic procedures should be followed up or communicated on days 7 and 14 in terms of the development of COVID-19 infection.
It is recommended that patients should be questioned in terms of COVID-19 infection before endoscopy, but rapid antigen testing and serology are not routinely recommended. Molecular diagnosis (PCR, amplification) tests are recommended for patients at risk for COVID-19 infection.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
İ̇zmi̇r
-
İzmir, İ̇zmi̇r, Turkey, 35170
- Tepecik Trh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children between the ages of 1-18 who will undergo endoscopic procedures
- Patients who can be questioned about COVID-19 infection before and on the 7th and 14th days after the procedure
- Patients who volunteered to study
Exclusion Criteria:
- Under 1 year and over 18 years of age
- Patients who could not be questioned about COVID-19 infection before the procedure and on the 7th and 14th days after the procedure
- Patients who not volunteered to study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Children who underwent endoscopic procedures
|
Esophagogastroscopy and colonoscopy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of participiants who was infected with Covid-19. normalization process of Covid-19 pandemic
Time Frame: 14 days
|
The number of participiants who had Covid-19 infection after the endoscopic procedures.
|
14 days
|
|
The time of seen covid 19 infection after the endoscopic procedures in participiants.
Time Frame: 14 days
|
The developed time of covid 19 infection after the endoscopic procedures in participiants.
|
14 days
|
|
The characteristics of patients with Covid-19 infection.
Time Frame: 14 days
|
The characteristics of patients with Covid-19 infection after the endoscopic procedures in participiants.
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: BETÜL AKSOY, MD, yes
- Study Chair: YELİZ ÇAĞAN APPAK, MD, yes
- Study Chair: DİLEK YILMAZ ÇİFTDOĞAN, PROFESSOR, yes
- Principal Investigator: MAŞALLAH BARAN, PROFESSOR, yes
- Study Chair: ŞENAY ONBAŞI KARABAĞ, MD, yes
Publications and helpful links
General Publications
- Gralnek IM, Hassan C, Beilenhoff U, Antonelli G, Ebigbo A, Pellise M, Arvanitakis M, Bhandari P, Bisschops R, Van Hooft JE, Kaminski MF, Triantafyllou K, Webster G, Pohl H, Dunkley I, Fehrke B, Gazic M, Gjergek T, Maasen S, Waagenes W, de Pater M, Ponchon T, Siersema PD, Messmann H, Dinis-Ribeiro M. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. Endoscopy. 2020 Jun;52(6):483-490. doi: 10.1055/a-1155-6229. Epub 2020 Apr 17.
- Gralnek IM, Hassan C, Beilenhoff U, Antonelli G, Ebigbo A, Pellise M, Arvanitakis M, Bhandari P, Bisschops R, Van Hooft JE, Kaminski MF, Triantafyllou K, Webster G, Voiosu AM, Pohl H, Dunkley I, Fehrke B, Gazic M, Gjergek T, Maasen S, Waagenes W, de Pater M, Ponchon T, Siersema PD, Messmann H, Dinis-Ribeiro M. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: An update on guidance during the post-lockdown phase and selected results from a membership survey. Endoscopy. 2020 Oct;52(10):891-898. doi: 10.1055/a-1213-5761. Epub 2020 Jul 14. No abstract available.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TepecikTRH1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
NCT04981769Not yet recruiting
-
NCT04885764Recruiting
-
NCT04608305Completed
-
NCT04864925Completed
-
NCT05045846Completed
-
NCT04973735Active, not recruiting
-
NCT04773756Completed
Clinical Trials on Endoscopic procedure
-
NCT00528775Terminated
-
NCT00505128Completed
-
NCT07594132Recruiting
-
NCT03724565CompletedEndoscopy, Gastrointestinal
-
NCT00987857UnknownEsophageal Cancer | Precancerous Condition
-
NCT05733663Completed
-
NCT01662024CompletedObesity | Overweight | Body Weight
-
NCT01164566TerminatedStage I Adenoid Cystic Carcinoma of the Oral Cavity | Stage I Mucoepidermoid Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Verrucous Carcinoma of the Larynx | Stage I Verrucous Carcinoma of the Oral Cavity | Stage II Adenoid Cystic Carcinoma of the Oral Cavity | Stage II Mucoepidermoid Carcinoma of the Oral Cavity | Stage II Squamous Cell Carcinoma of the Hypopharynx